Cell Therapy Clinical Trial Services Market Size

Cell Therapy Clinical Trial Services Market size was valued at USD 2.6 billion in 2023, growing at a CAGR of 10.6% between 2024 and 2032. The global market is experiencing dynamic growth driven by factors such as the growing prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders that increase the demand for innovative treatments like cell therapy, leading to more clinical trials.

Moreover, continuous advancements in cell therapy technologies, such as CAR-T cell therapy and stem cell therapy, are expanding the scope of clinical trials services, thus, driving the market growth. For instance, in February 2024, BioNTech SE a next-generation immunotherapy company and Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization and pending regulatory authorizations. In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement. Thus, the collaboration with Autolus enables BioNTech SE to expand BNT211 program into trials for multiple cancer indications in a cost-efficient way. Thus, widespread usage of regulatory services will spur the market growth.

Cell therapy clinical trial services encompass a range of activities and support mechanisms provided by specialized organizations to facilitate the planning, execution, and management of clinical trials focused on cell-based therapies. These services are designed to assist pharmaceutical companies, biotechnology firms, academic institutions, and other stakeholders in navigating the complex process of conducting clinical trials for cell therapies.